Update
$TenX Keane Acquisition (TENK.US)$ $Citius Pharmaceuticals (CTXR.US)$ Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
Granted FDA approval of LYMPHIR™ in treatment of cutaneous T-cell lymphoma
Completed merger of oncology subsidiary with TenX Keane; Citius Oncology expected to begin trading on Nasdaq on August 13, 2024 under ticker CTOR
Achieved primary and secondary endpoints of Mino-Lok® Phase 3 Trial
Granted FDA approval of LYMPHIR™ in treatment of cutaneous T-cell lymphoma
Completed merger of oncology subsidiary with TenX Keane; Citius Oncology expected to begin trading on Nasdaq on August 13, 2024 under ticker CTOR
Achieved primary and secondary endpoints of Mino-Lok® Phase 3 Trial
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
萬軍無兵策天鳳 : Did the opening on the 13th directly become a ctor?
Trytosaveabit OP 萬軍無兵策天鳳 : Yes it is supposed to open tomorrow under the ticker CTOR! If you have shares? They will be converted automatically for you! You don’t need to do anything
萬軍無兵策天鳳 Trytosaveabit OP : I feel like CTOR will skyrocket, but there's no good news for ctxr![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP 萬軍無兵策天鳳 : It could! Some ticker changes do go up a lot! And CTXR did have FDA approval News August 8th
萬軍無兵策天鳳 : But CTXR has already fallen so much... Although we knew that some people would lock in profits and exit, what we didn't expect was that it would simply not rise much and start to plummet.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")